DE69011853D1 - System zur bearbeitung von hefe, welches eine zur bearbeitungsstelle benachbarte negativ geladene aminosäure beeinhaltet. - Google Patents

System zur bearbeitung von hefe, welches eine zur bearbeitungsstelle benachbarte negativ geladene aminosäure beeinhaltet.

Info

Publication number
DE69011853D1
DE69011853D1 DE69011853T DE69011853T DE69011853D1 DE 69011853 D1 DE69011853 D1 DE 69011853D1 DE 69011853 T DE69011853 T DE 69011853T DE 69011853 T DE69011853 T DE 69011853T DE 69011853 D1 DE69011853 D1 DE 69011853D1
Authority
DE
Germany
Prior art keywords
amino acid
negatively charged
yeast
terminal end
charged amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69011853T
Other languages
English (en)
Other versions
DE69011853T3 (de
DE69011853T2 (de
Inventor
Soren Bjorn
Kjeld Norris
Fanny Norris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69011853(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK494189A external-priority patent/DK494189D0/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of DE69011853D1 publication Critical patent/DE69011853D1/de
Application granted granted Critical
Publication of DE69011853T2 publication Critical patent/DE69011853T2/de
Publication of DE69011853T3 publication Critical patent/DE69011853T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • C07K14/8117Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14Fungi; Culture media therefor
    • C12N1/16Yeasts; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/61Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Processing Of Solid Wastes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
DE69011853T 1989-03-03 1990-03-01 System zur bearbeitung von hefe, welches eine zur bearbeitungsstelle benachbarte negativ geladene aminosäure beeinhaltet. Expired - Lifetime DE69011853T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK105489A DK105489D0 (da) 1989-03-03 1989-03-03 Polypeptid
DK494189A DK494189D0 (da) 1989-10-06 1989-10-06 Polypeptid
PCT/DK1990/000058 WO1990010075A1 (en) 1989-03-03 1990-03-01 Yeast processing system comprising a negatively charged amino acid adjacent to the processing site

Publications (3)

Publication Number Publication Date
DE69011853D1 true DE69011853D1 (de) 1994-09-29
DE69011853T2 DE69011853T2 (de) 1994-12-15
DE69011853T3 DE69011853T3 (de) 1998-06-25

Family

ID=26065137

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69011853T Expired - Lifetime DE69011853T3 (de) 1989-03-03 1990-03-01 System zur bearbeitung von hefe, welches eine zur bearbeitungsstelle benachbarte negativ geladene aminosäure beeinhaltet.

Country Status (23)

Country Link
US (3) US5395922A (de)
EP (1) EP0461165B2 (de)
JP (1) JP2609367B2 (de)
KR (1) KR970005928B1 (de)
AT (1) ATE110414T1 (de)
AU (1) AU624694B2 (de)
CA (1) CA2050336C (de)
CZ (1) CZ285239B6 (de)
DD (1) DD296965A5 (de)
DE (1) DE69011853T3 (de)
DK (2) DK105489D0 (de)
ES (1) ES2062514T5 (de)
FI (1) FI104985B (de)
HU (2) HU215538B (de)
IE (1) IE66469B1 (de)
IL (1) IL93609A (de)
NO (2) NO304236B1 (de)
NZ (1) NZ232742A (de)
PL (1) PL163532B1 (de)
RU (1) RU2194758C2 (de)
UA (1) UA27706C2 (de)
WO (1) WO1990010075A1 (de)
ZA (1) ZA901476B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591603A (en) * 1987-08-28 1997-01-07 Novo Nordisk A/S Process for preparing aprotinin and aprotinin analogs in yeast cells
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
EP0472658A4 (en) * 1989-05-19 1992-08-26 Biotechnology Res & Dev Fusion proteins having an in vivo post-translational modification site and methods of manufacture and purification
GB9015825D0 (en) * 1990-07-18 1990-09-05 Ciba Geigy Ag In vitro processing of fusion proteins
DK300090D0 (da) * 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FI92601C (fi) * 1992-03-11 1994-12-12 Marja Makarow Menetelmä hyötyproteiinien erittämiseksi hiivoista
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
DE4417353A1 (de) * 1994-05-18 1996-01-25 Bayer Ag Verfahren zur Herstellung von rekombinantem Aprotinin und rekombinanten Aprotinin Varianten mit der natürlichen N-terminlaen Sequenz
IL114160A (en) * 1994-06-17 2006-12-31 Novo Nordisk As Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
DE19629982A1 (de) 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
EP0948538B1 (de) * 1996-12-13 2008-06-11 Novartis Vaccines and Diagnostics, Inc. Analyse und separation von pdgf-proteinen
DE69735242T2 (de) * 1996-12-20 2006-09-21 Novo Nordisk A/S N-terminal verlängerte proteine exprimiert in hefe
JP2001527387A (ja) * 1997-01-24 2001-12-25 ノボ ノルディスク アクティーゼルスカブ 合成リーダーペプチド配列
US6046000A (en) * 1997-11-07 2000-04-04 Millennium Biotherapeutics, Inc. Method for identifying genes encoding signal sequences
WO1999037793A1 (en) 1998-01-23 1999-07-29 Novo Nordisk A/S Process for making desired polypeptides in yeast
ATE474930T1 (de) 1999-12-29 2010-08-15 Novo Nordisk As Verfahren zur herstellung von insulinvorläufern und analogen von insulinvorläufern mit verbesserter fermentationsausbeute in hefe
AU2001266557A1 (en) * 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
WO2003059934A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (de) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin Fusionsproteine
US7309505B2 (en) 2002-09-13 2007-12-18 Cornell Research Foundation, Inc. Using mutations to improve Aspergillus phytases
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1687428A1 (de) 2003-11-14 2006-08-09 Novo Nordisk A/S Verfahren zur herstellung von acyliertem insulin
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー/エス 単鎖インシュリン
EP1917363B1 (de) 2005-08-16 2011-06-22 Novo Nordisk A/S Verfahren zur herstellung reifer insulinpolypeptide
JP5202338B2 (ja) 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー/エス 新規インシュリン誘導体
US8198046B2 (en) 2006-07-11 2012-06-12 Danisco Us Inc. KEX2 cleavage regions of recombinant fusion proteins
US20080026376A1 (en) * 2006-07-11 2008-01-31 Huaming Wang KEX2 cleavage regions of recombinant fusion proteins
EP2404934A1 (de) 2006-09-22 2012-01-11 Novo Nordisk A/S Proteaseresistente Insulinanaloga
ES2464282T3 (es) 2006-09-27 2014-06-02 Novo Nordisk A/S Método para preparar polipéptidos de insulina madura
JP5404411B2 (ja) 2006-11-22 2014-01-29 ノボ・ノルデイスク・エー/エス 活性化カルボキシペプチダーゼの製造方法
EP2170945A1 (de) 2007-07-16 2010-04-07 Novo Nordisk A/S Proteasestabilisierte pegylierte insulinanaloga
JP5710253B2 (ja) 2007-08-13 2015-04-30 ノボ・ノルデイスク・エー/エス 速効型インスリンアナログ
ES2548304T3 (es) 2007-08-15 2015-10-15 Novo Nordisk A/S Análogos de la insulina que contienen una fracción acilo y alquilenglicol
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー/エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
US8501449B2 (en) 2007-12-04 2013-08-06 Proteon Therapeutics, Inc. Recombinant elastase proteins and methods of manufacturing and use thereof
AU2009226910B2 (en) 2008-03-18 2014-02-06 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
EP2262539B1 (de) 2008-04-01 2015-07-15 Novo Nordisk A/S Insulin-albumin-konzentrate
WO2010103546A2 (en) * 2009-03-12 2010-09-16 Bigtec Private Limited A polynucleotide and polypeptide sequence and methods thereof
HUE027239T2 (en) 2009-06-26 2016-10-28 Novo Nordisk As Preparation containing insulin, nicotinamide and arginine
EP2504355B1 (de) 2009-11-25 2015-07-22 Novo Nordisk A/S Verfahren zur herstellung von polypeptiden
EP2526117B1 (de) 2010-01-22 2015-05-06 Novo Nordisk A/S Verfahren zur herstellung von fgf-21 mit geringer o-glykosylierung
US8853155B2 (en) 2010-06-23 2014-10-07 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
JP6013330B2 (ja) 2010-06-23 2016-10-25 ノヴォ ノルディスク アー/エス 追加のジスルフィド結合を含有するヒトインスリン
CN102947331B (zh) 2010-06-23 2016-08-03 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素类似物
MX2013006174A (es) 2010-12-14 2013-07-15 Novo Nordisk As Preparacion que comprende insulina, nicotinamida y un aminoacido.
JP2013545782A (ja) 2010-12-14 2013-12-26 ノヴォ ノルディスク アー/エス 長時間作用型インスリンと組み合わせた速効型インスリン
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
RU2460795C1 (ru) * 2011-07-06 2012-09-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") Способ микробиологического синтеза секретируемого соматотропина человека и штамм дрожжей saccharomyces cerevisiae - продуцент секретируемого соматотропина человека
WO2013186138A1 (en) 2012-06-14 2013-12-19 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
CN103254277B (zh) * 2013-05-03 2017-02-08 南京工业大学 强分泌性信号肽增强小肽模序及其应用
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー/エス 成熟インスリンポリペプチドを作製するための方法
PL233560B1 (pl) 2014-12-05 2019-10-31 Mabion Spolka Akcyjna Sposób otrzymywania insuliny lub analogu insuliny z prekursora rekombinowanego białka
WO2016144658A1 (en) 2015-03-10 2016-09-15 Merck Sharp & Dohme Corp. Process for preparing recombinant insulin using microfiltration
JP6983075B2 (ja) 2015-06-02 2021-12-17 ノヴォ ノルディスク アー/エス 極性の組換え延長部を有するインスリン
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
CN108026156A (zh) 2015-08-25 2018-05-11 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
AR106364A1 (es) 2015-08-25 2018-01-10 Novo Nordisk As Derivados de insulina y sus usos médicos
KR102043067B1 (ko) * 2017-08-08 2019-11-11 엘지전자 주식회사 차량용 사이드 미러 및 차량
WO2019034726A1 (en) 2017-08-17 2019-02-21 Novo Nordisk A/S NOVEL ACYLATED INSULIN ANALOGUES AND USES THEREOF
US11498951B2 (en) 2019-12-11 2022-11-15 Novo Nordisk A/S Insulin analogues and uses thereof
WO2023144240A1 (en) 2022-01-26 2023-08-03 Novo Nordisk Research Centre Oxford Limited Glucose sensitive insulin derivatives and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5712580A (en) * 1979-04-05 1980-10-09 James Joseph Connell Engine charging and scavenging
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
JPS60501140A (ja) * 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
US4588684A (en) * 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
EP0195680A3 (de) * 1985-03-21 1987-06-10 Immunex Corporation Proteinsynthese mit einem Identifizierungspeptid
JPS6236183A (ja) * 1985-06-20 1987-02-17 ザ・サルク・インステイチユ−ト・バイオテクノロジ−/インダストリアル・アソシエイツ・インコ−ポレ−テツド サツカロミセス・セレビシエからのポリペプチドの発現および分泌
MC1834A1 (fr) * 1986-07-10 1988-06-03 Transgene Sa Bloc fonctionnel d'adn et plasmide codant pour l'hirudine,levure transformee,procede de preparation de l'hirudine,hirudine obtenue et son utilisation
DK175535B1 (da) * 1987-03-04 2004-11-29 Daiichi Suntory Pharma Co Ltd Fremgangsmåde til fremstilling af et fysiologisk aktivt cysteinholdigt peptid
EP0371041A1 (de) * 1987-06-24 1990-06-06 Novo Nordisk A/S Verfahren für die herstellung eines proteins oder polypeptides, dns-sequenz, die dieses polypeptid kodiert, mikroorganismus, der diese dns-sequenz beinhaltet, sowie das polypeptid und seine verwendung als pharmazeutisches präparat
DK450187D0 (da) * 1987-08-28 1987-08-28 Novo Industri As Fremgangsmaade til fremstilling af proteiner
DK463887D0 (da) * 1987-09-07 1987-09-07 Novo Industri As Gaerleader
JPH01240191A (ja) * 1988-02-16 1989-09-25 Green Cross Corp:The 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
DK336188D0 (da) * 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
EP0387319B1 (de) * 1988-07-23 1996-03-06 Delta Biotechnology Limited Sekretorische leader-sequenzen
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid

Also Published As

Publication number Publication date
CA2050336C (en) 2000-01-18
CZ103990A3 (cs) 1999-03-17
US5510249A (en) 1996-04-23
UA27706C2 (uk) 2000-10-16
DK105489D0 (da) 1989-03-03
WO1990010075A1 (en) 1990-09-07
KR920701452A (ko) 1992-08-11
DD296965A5 (de) 1991-12-19
JPH04504846A (ja) 1992-08-27
DE69011853T3 (de) 1998-06-25
US5395922A (en) 1995-03-07
HU902376D0 (en) 1991-11-28
FI914125A0 (fi) 1991-09-02
IL93609A (en) 2001-11-25
IL93609A0 (en) 1990-12-23
PL163532B1 (pl) 1994-04-29
IE66469B1 (en) 1995-12-27
NO913427L (no) 1991-11-01
EP0461165B2 (de) 1998-03-25
NO913427D0 (no) 1991-09-02
NO974899D0 (no) 1997-10-23
ES2062514T5 (es) 1998-06-01
NO304236B1 (no) 1998-11-16
CZ285239B6 (cs) 1999-06-16
FI104985B (fi) 2000-05-15
HU215538B (hu) 1999-01-28
DK0461165T3 (da) 1994-11-21
JP2609367B2 (ja) 1997-05-14
US5514585A (en) 1996-05-07
RU2194758C2 (ru) 2002-12-20
ATE110414T1 (de) 1994-09-15
IE900749L (en) 1990-09-03
CA2050336A1 (en) 1990-09-04
NO974899L (no) 1997-10-23
DE69011853T2 (de) 1994-12-15
AU5261290A (en) 1990-09-26
AU624694B2 (en) 1992-06-18
HUT58370A (en) 1992-02-28
ZA901476B (en) 1990-11-28
KR970005928B1 (ko) 1997-04-22
NZ232742A (en) 1991-10-25
ES2062514T3 (es) 1994-12-16
EP0461165B1 (de) 1994-08-24
HU211600A9 (en) 1995-12-28
EP0461165A1 (de) 1991-12-18

Similar Documents

Publication Publication Date Title
DE69011853D1 (de) System zur bearbeitung von hefe, welches eine zur bearbeitungsstelle benachbarte negativ geladene aminosäure beeinhaltet.
Ishiura et al. Studies of a Calcium-Activated Neutral Protease from Chicken Skeletal Muscle II. Substrate Specificity
KR890010199A (ko) 활성화된 사람의 단백질 c의 직접 발현용 벡터 및 화합물
ZA8860B (en) Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host,process,expression vector and recombinant host therefor and pharmaceutical use thereof
IL76107A (en) Method of removing n-terminal amino acid residues from eucaryotic polypeptide analogs and polypeptides produced thereby
DE69432185D1 (de) Eine sekretionssequenz für die herstellung von heterologen proteinen in hefe
DE69735242D1 (de) N-terminal verlängerte proteine exprimiert in hefe
DE3873273D1 (de) Verfahren zur selektiven spaltung von fusionsproteinen.
AU651830B2 (en) In vitro processing of fusion proteins
Bjorn et al. Yeast processing system

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Free format text: GRUENECKER, KINKELDEY, STOCKMAIR & SCHWANHAEUSSER, ANWALTSSOZIETAET, 80538 MUENCHEN

8366 Restricted maintained after opposition proceedings